Nutra Pharma Is Providing an Update on the Company's Efforts to Market and Distribute Their Over-the-Counter (OTC) Pain Reliever, Nyloxin(R) in India
CORAL SPRINGS, FL--(Marketwired - Apr 15, 2015) - Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is providing an update regarding their plan to market their over-the-counter (OTC) pain reliever, Nyloxin® through S.Zhaveri Pharmakem for distribution throughout India. Nutra Pharma previously announced that they had shipped their initial test orders of Nyloxin® in February to ensure Customs clearance before escalating order sizes and frequency. Nutra Pharma management has been working in Mumbai this week to finalize their plans for the national rollout of Nyloxin.
"Now that we have successfully sent test shipments of our products to our partners in India, I needed to travel to Mumbai this week to work on the next steps that we will take to maximize the potential of this enormous market," stated Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. "The Indian people do not like opiate drugs and really do not provide any current products that would be competitive to Nyloxin. This could feasibly allow our products to capture a large share of the OTC pain market here," he continued. "We expect to start shipping sample orders for initial promotions shortly, with larger orders to fill the pipeline in the next 3 months," he concluded.
According to a 1998 study published in the Journal of the American Medical Association (JAMA), it was estimated that 19% of patients evaluated in India suffered from persistent pain. An additional 2007 report from the Journal of Pain and Symptom Management, documented that only 0.4% of India's population in need of opioids for pain relief had access to them. In a 2014 Euromonitor report, the analgesic market in India reached over $274 million annually but consisted mostly of low-cost, OTC therapies.
Nyloxin® is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin® is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin® is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain in humans under the brand Nyloxin®; and for pain in companion animals under the brand Pet Pain-Away. For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's to market and distribute products in India should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.